Cargando…

Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors

Sabatolimab is a novel immunotherapy with immuno‐myeloid activity that targets T‐cell immunoglobulin domain and mucin domain‐3 (TIM‐3) on immune cells and leukemic blasts. It is being evaluated for the treatment of myeloid malignancies in the STIMULUS clinical trial program. The objective of this an...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Siyan, Zhang, Na, Rinne, Mikael L., Sun, Haiying, Stein, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681456/
https://www.ncbi.nlm.nih.gov/pubmed/37186155
http://dx.doi.org/10.1002/psp4.12962